The Discounted Cash Flow (DCF) valuation of Apellis Pharmaceuticals Inc (APLS) is 6.31 USD. With the latest stock price at 41.03 USD, the upside of Apellis Pharmaceuticals Inc based on DCF is -84.6%.
Based on the latest price of 41.03 USD and our DCF valuation, Apellis Pharmaceuticals Inc (APLS) is a sell. selling Apellis stocks now will result in a potential gain of 84.6%.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 8.1% | 7.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 3.52 - 25.05 | 6.31 |
| Upside | -91.4% - -38.9% | -84.6% |